xRead - September 2022

Wise et al.

Page 332

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Evidence for the effect of medication on allergy skin test reactivity Study Year LOE Study design Study groups Clinical endpoints Conclusion Kupczyk et al. 871 2007 1b DBPCT, crossover Atopic subjects (n = 21). SPT with histamine, codeine, allergen, negative control after 5 days of ranitidine, loratadine, or placebo Wheal, flare measured in mm. Pruritis measured with 10-point scale Relative to placebo, ranitidine reduced histamine wheal (41%) and flare (16%); and allergen wheal (23%) and flare (22%). Loratadine reduced histamine wheal (51%) and flare (33%); and allergen wheal (40%) and flare (44%), respectively. Ranitidine and loratadine both reduced pruritis score by almost 30%. Spergel et al. 888 2004 1b RDBT, within subject comparison Atopic dermatitis and AR or asthma (n = 12 adults). Vehicle or pimecrolimus on each arm Allergen SPT wheal and flare, before and after topical 1% pimecrolimus cream 1% pimecrolimus cream does not significantly impact allergy skin test results. Hill & Krouse 876 2003 1b RDBPCT Atopic subjects (n = 23) Intradermal whealing response after loratadine, montelukast, or placebo treatment

Loratadine, but not montelukast, reduced the intradermal wheal diameter after allergen injection.

Fexofenadine significantly reduced SPT wheal size compared to placebo. None of the 23 herbal preparations tested showed a statistically significant effect on wheal size compared to placebo.

Omalizumab caused significant reduction in SPT wheal size compared to placebo.

2 weeks of azelastine inhibited wheal and flare in some patients. Histamine skin test responses returned to baseline at 48 hours after cessation. Fexofenadine and loratadine both inhibited SPT wheal and flare response for 24 hours.

Ranitidine reduced the histamine-induced wheal and flare by 22%. No significant

reduction in compound 48/80-induced wheal and flare. Pipkorn et al. 891 1989 1b RDBPCT AR patients (n = 10) Allergen SPT wheal and flare before and Andersson & Pipkorn 883 Slott & Zweiman 879 crossover

Clobetasol treated skin had significantly reduced wheal and flare response to allergen. Histamine-induced wheal was reduced at 4 weeks by topical steroid.

Topical clobetasol significantly suppresses allergen-induced wheal and flare response.

No effect of 7 days of methylprednisolone on intradermal wheal size.

Histamine 1 mg/mL wheal at baseline and 4 hours after single dose of herbal preparation

SPTs for allergen before and 16 weeks after treatment

Pearlman et al. 869 2003 1b RPCT SAR patients (n = 78) Inhibition of histamine-induced wheal after single dose or 2 weeks of azelastine nasal spray 1997 1b RDBPCT,

Adult males (n = 20) SPT wheal and flare response after single day dosing of PO fexofenadine and loratadine

1989 1b RDBT Healthy subjects (n = 23) Histamine-induced and compound 48/80 induced skin prick wheal and flare after placebo or ranitidine 150 mg ×7 doses

after 2 to 4 weeks of twice daily clobetasol cream applied to forearm skin test sites

1987 1b DBPCT AR patients (n = 17) Effect of topical clobetasol (BID application for 1 week) on histamine and allergen SPT response 1974 1b DBPCT,

Atopic patients (n = 15) Intradermal wheal size differences for histamine, allergen, and compound 48/80

TABLE VIII.E.4.a-1.

More et al. 889 2003 1b RDBPCT Healthy volunteers (n = 15). Single blinded dose of placebo, fexofenadine, 23 other herbal preparations. Minimum 72 hour washout period between doses Simons & Simons 865

Noga et al. 890 2003 1b RDBPCT Moderate-severe asthmatics (n = 35) treated with placebo or omalizumab crossover Miller & Nelson 870

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.